ClinicalTrials.gg
Active, not recruitingNCT04860947NFL OCTUpdated Oct 22, 2026

Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients

An observational study in Multiple Sclerosis, sponsored by Centre Hospitalier Universitaire de Nīmes. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational

How we know

Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes — 1 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Centre Hospitalier Universitaire de Nīmes.

Started
2019
with 2 others
Observational
7 of 13
none open now
Registered
9th of 13
by date

Among the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, this one is one of 3 that started in 2019, is one of 7 observational ones, and was the 9th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, or all of them as a file.
02

Study summary

The investigators hypothesize that serum neurofilament-light chain (NfL) levels at baseline and decrease of the macular ganglion cell complex (GCC) thickness at one year vs. baseline are as good as progression of whole brain atrophy at one year vs. baseline to predict later evolution of neurological disability in multiple sclerosis patients.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • GFAP
  • NfL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population is composed of consecutive adult patients, of both sexes, recruited during consultations for a CIS, RRMS or progressive MS at the Neurology department of Nîmes University Hospital (CHU). The patients recruited will have an EDSS score comprised between 0 - 7.0.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has been correctly informed.
  • The patient must have given their informed and signed consent.
  • The patient must be insured or beneficiary of a health insurance plan.
  • The patient is at least (≥)18 years old.
  • The patient has experienced a CIS, has currently a RRMS or progressive MS with:

    • Less than 10 years of disease duration;
    • With or without DMD;
    • EDSS score 0 - 7.0.

Exclusion criteria

Exclusion Criteria:

  • The patient is in an exclusion period determined by a previous study.
  • The patient is under judicial protection.
  • The patient refuses to sign the consent.
  • It is impossible to correctly inform the patient (Inability to understand the study, language problem).
  • The patient is pregnant or breast-feeding.
  • Patient has a bilateral optic neuritis or other significant ophthalmological antecedent.
  • Patient with MRI .
  • patient has a contraindication to gadolinium injection
  • The patient has bilateral optic neuritis or other significant ophthalmological antecedent
  • Patient is having a relapse or has had a relapse in the last 3 months
  • The patient has a severe psychiatric illness
  • The patient has severe chronic alcoholism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • MS patients

    Diagnostic Test: Brain MRI · Diagnostic Test: Spinal Cord MRI · Diagnostic Test: Retinal imaging

Interventions

  • Diagnostic testBrain MRI

    * Axial DWI with ADC card * Axial 2D TSE T2/DP or 3DT2 * Gadolinium injection (0.1 mmol/kg) * 3D Fluid-attenuated inversion recovery * 3D T1 with Gadolinium injection.

  • Diagnostic testSpinal Cord MRI

    Sagittal T2 Sagittal T1 with Gadolinium injection

  • Diagnostic testRetinal imaging

    spectral-domain high definition optical coherence tomography

06

What researchers measure

Primary outcomes

  1. Change in serum Neurofilament Light Chain serum levels since baseline

    pg/mL; measured by digital ELISA

    Time frame: Baseline; 1 year

  2. Change in serum Glial Fibrillary Acidic Protein (GFAP) serum levels since baseline

    pg/mL; measured by digital ELISA

    Time frame: Baseline; 1 year

  3. Change in Ganglion Cell Complex thickness since baseline

    Measured by Optical Coherence Tomography

    Time frame: Baseline; 1 year

  4. Change in whole brain volume since baseline

    Assessed by MRI

    Time frame: Baseline; 1 year

  5. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: Baseline

  6. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 3 years

Secondary outcomes

  1. Whole brain volume

    assessed by MRI

    Time frame: Inclusion

  2. Whole brain volume

    assessed by MRI

    Time frame: 6 Months

  3. Whole brain volume

    assessed by MRI

    Time frame: 1 Year

  4. Whole brain volume

    assessed by MRI

    Time frame: 2 years

  5. Whole brain volume

    assessed by MRI

    Time frame: 3 Years

  6. Whole brain volume

    assessed by MRI

    Time frame: 4 Years

  7. Whole brain volume

    assessed by MRI

    Time frame: 5 years

  8. Whole brain volume

    assessed by MRI

    Time frame: any relapse (max 5 years)

  9. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: Inclusion

  10. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 6 Months

  11. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 1 year

  12. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 18 months

  13. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 2 years

  14. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 2.5 years

  15. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 3 years

  16. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 3.5 years

  17. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 4 years

  18. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 4.5 years

  19. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: 5 years

  20. Expanded Disability Status Scale

    Eight functional systems scored on a scale of 0 (no disability) to 5 or 6 (more severe disability)

    Time frame: Any relapse (Maximum 5 years)

  21. Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness

    assessed by Optical Coherence Tomography

    Time frame: Inclusion

  22. Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness

    assessed by Optical Coherence Tomography

    Time frame: 6 Months

  23. Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness

    assessed by Optical Coherence Tomography

    Time frame: 1 Year

  24. Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness

    assessed by Optical Coherence Tomography

    Time frame: 18 Months

  25. Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness

    assessed by Optical Coherence Tomography

    Time frame: 2 years

  26. Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness

    assessed by Optical Coherence Tomography

    Time frame: 3 Years

  27. Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness

    assessed by Optical Coherence Tomography

    Time frame: 4 Years

  28. Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness

    assessed by Optical Coherence Tomography

    Time frame: 5 Years

  29. Peripapillary Retinal Nerve Fibre Layer atrophy and Ganglion Cell Complex thickness

    assessed by Optical Coherence Tomography

    Time frame: Any relapse (maximum 5 Years)

  30. Gadolinium-enhanced lesions

    assessed by MRI

    Time frame: Inclusion

  31. Gadolinium-enhanced lesions

    assessed by MRI

    Time frame: 6 Months

  32. Gadolinium-enhanced lesions

    assessed by MRI

    Time frame: 1 Year

  33. Gadolinium-enhanced lesions

    assessed by MRI

    Time frame: 2 years

  34. Gadolinium-enhanced lesions

    assessed by MRI

    Time frame: 3 Years

  35. Gadolinium-enhanced lesions

    assessed by MRI

    Time frame: 4 Years

  36. Gadolinium-enhanced lesions

    assessed by MRI

    Time frame: 5 Years

  37. Gadolinium-enhanced lesions

    assessed by MRI

    Time frame: Any relapse (Maximum 5 Years)

  38. T2 lesion volume,

    assessed by MRI

    Time frame: Inclusion

  39. T2 lesion volume,

    assessed by MRI

    Time frame: 6 Months

  40. T2 lesion volume,

    assessed by MRI

    Time frame: 1 Year

  41. T2 lesion volume,

    assessed by MRI

    Time frame: 2 years

  42. T2 lesion volume,

    assessed by MRI

    Time frame: 3 Years

  43. T2 lesion volume,

    assessed by MRI

    Time frame: 4 Years

  44. T2 lesion volume,

    assessed by MRI

    Time frame: 5 years

  45. T2 lesion volume,

    assessed by MRI

    Time frame: Any relapse (maximum 5 years)

  46. Grey matter atrophy

    assessed by MRI

    Time frame: Inclusion

  47. Grey matter atrophy

    assessed by MRI

    Time frame: 6 Months

  48. Grey matter atrophy

    assessed by MRI

    Time frame: 1 Year

  49. Grey matter atrophy

    assessed by MRI

    Time frame: 2 years

  50. Grey matter atrophy

    assessed by MRI

    Time frame: 3 Years

  51. Grey matter atrophy

    assessed by MRI

    Time frame: 4 Years

  52. Grey matter atrophy

    assessed by MRI

    Time frame: 5 Years

  53. Grey matter atrophy

    assessed by MRI

    Time frame: Any relapse (maximum 5 Years)

  54. White matter atrophy

    assessed by MRI

    Time frame: Inclusion

  55. White matter atrophy

    assessed by MRI

    Time frame: 6 Months

  56. White matter atrophy

    assessed by MRI

    Time frame: 1 Year

  57. White matter atrophy

    assessed by MRI

    Time frame: 2 years

  58. White matter atrophy

    assessed by MRI

    Time frame: 3 Years

  59. White matter atrophy

    assessed by MRI

    Time frame: 4 Years

  60. White matter atrophy

    assessed by MRI

    Time frame: 5 years

  61. White matter atrophy

    assessed by MRI

    Time frame: Any relapse (maximum 5 years)

  62. Thalamic atrophy

    assessed by MRI

    Time frame: Inclusion

  63. Thalamic atrophy

    assessed by MRI

    Time frame: 6 Months

  64. Thalamic atrophy

    assessed by MRI

    Time frame: 1 Year

  65. Thalamic atrophy

    assessed by MRI

    Time frame: 2 years

  66. Thalamic atrophy

    assessed by MRI

    Time frame: 3 Years

  67. Thalamic atrophy

    assessed by MRI

    Time frame: 4 Years

  68. Thalamic atrophy

    assessed by MRI

    Time frame: 5 years

  69. Thalamic atrophy

    assessed by MRI

    Time frame: Any relapse (maximum 5 years)

  70. Disease modifying drugs classification

    Drug class (1st, 2nd or 3rd line)

    Time frame: Inclusion

  71. Disease modifying drugs classification

    Drug class (1st, 2nd or 3rd line)

    Time frame: until end of study (5 years)

  72. serum NfL levels

    pg/mL; measured by digital ELISA

    Time frame: 6 Months

  73. serum GFAP levels

    pg/mL; measured by digital ELISA

    Time frame: 6 Months

  74. serum NfL levels

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  75. serum GFAP levels

    pg/mL; measured by digital ELISA

    Time frame: 2 years

  76. serum NfL levels

    pg/mL; measured by digital ELISA

    Time frame: 3 years

  77. serum GFAP levels

    pg/mL; measured by digital ELISA

    Time frame: 3 years

  78. serum NfL levels

    pg/mL; measured by digital ELISA

    Time frame: 4 years

  79. serum GFAP levels

    pg/mL; measured by digital ELISA

    Time frame: 4 years

  80. serum NfL levels

    pg/mL; measured by digital ELISA

    Time frame: 5 years

  81. serum GFAP levels

    pg/mL; measured by digital ELISA

    Time frame: 5 years

  82. serum NfL levels

    pg/mL; measured by digital ELISA

    Time frame: Any relapse (maximum 5 years)

  83. serum GFAP levels

    pg/mL; measured by digital ELISA

    Time frame: Any relapse (maximum 5 years)

  84. Multiple Sclerosis Functional Composite

    21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)

    Time frame: Inclusion

  85. Multiple Sclerosis Functional Composite

    21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)

    Time frame: 6 Months

  86. Multiple Sclerosis Functional Composite

    21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)

    Time frame: 1 Year

  87. Multiple Sclerosis Functional Composite

    21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)

    Time frame: 2 years

  88. Multiple Sclerosis Functional Composite

    21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)

    Time frame: 3 years

  89. Multiple Sclerosis Functional Composite

    21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)

    Time frame: 4 years

  90. Multiple Sclerosis Functional Composite

    21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)

    Time frame: 5 years

  91. Multiple Sclerosis Functional Composite

    21-item test that includes 3 different functional subtests: the timed 25-Foot Walk, the 9-Hole Peg Test and the Paced Auditory Serial Addition Test (PASAT)

    Time frame: Any relapse (maximum 5 years)

  92. Time to walk 100 meters

    Seconds

    Time frame: Inclusion

  93. Time to walk 100 meters

    Seconds

    Time frame: 6 Months

  94. Time to walk 100 meters

    Seconds

    Time frame: 1 Year

  95. Time to walk 100 meters

    Seconds

    Time frame: 2 years

  96. Time to walk 100 meters

    Seconds

    Time frame: 3 years

  97. Time to walk 100 meters

    Seconds

    Time frame: 4 years

  98. Time to walk 100 meters

    Seconds

    Time frame: 5 years

  99. Time to walk 100 meters

    Seconds

    Time frame: Any relapse (maximum 5 years)

  100. 2 Minute walking distance

    Meters

    Time frame: Inclusion

  101. 2 Minute walking distance

    Meters

    Time frame: 6 Months

  102. 2 Minute walking distance

    Meters

    Time frame: 1 Year

  103. 2 Minute walking distance

    Meters

    Time frame: 2 years

  104. 2 Minute walking distance

    Meters

    Time frame: 3 years

  105. 2 Minute walking distance

    Meters

    Time frame: 4 years

  106. 2 Minute walking distance

    Meters

    Time frame: 5 years

  107. 2 Minute walking distance

    Meters

    Time frame: Any relapse (maximum 5 years)

  108. Cognitive Impairment

    Symbol Digit Modalities Test

    Time frame: Inclusion

  109. Cognitive Impairment

    Symbol Digit Modalities Test

    Time frame: 6 months

  110. Cognitive Impairment

    Symbol Digit Modalities Test

    Time frame: 1 Year

  111. Cognitive Impairment

    Symbol Digit Modalities Test

    Time frame: 2 years

  112. Cognitive Impairment

    Symbol Digit Modalities Test

    Time frame: 3 years

  113. Cognitive Impairment

    Symbol Digit Modalities Test

    Time frame: 4 years

  114. Cognitive Impairment

    Symbol Digit Modalities Test

    Time frame: 5 years

  115. Cognitive Impairment

    Symbol Digit Modalities Test

    Time frame: Any relapse (maximum 5 years)

  116. Cognitive evaluation

    Brief International Cognitive Assessment for Multiple Sclerosis

    Time frame: Inclusion

  117. Cognitive evaluation

    Brief International Cognitive Assessment for Multiple Sclerosis

    Time frame: 6 Months

  118. Cognitive evaluation

    Brief International Cognitive Assessment for Multiple Sclerosis

    Time frame: 1 Year

  119. Cognitive evaluation

    Brief International Cognitive Assessment for Multiple Sclerosis

    Time frame: 2 years

  120. Cognitive evaluation

    Brief International Cognitive Assessment for Multiple Sclerosis

    Time frame: 3 years

  121. Cognitive evaluation

    Brief International Cognitive Assessment for Multiple Sclerosis

    Time frame: 4 years

  122. Cognitive evaluation

    Brief International Cognitive Assessment for Multiple Sclerosis

    Time frame: 5 years

  123. Cognitive evaluation

    Brief International Cognitive Assessment for Multiple Sclerosis

    Time frame: Any relapse (maximum 5 years)

  124. Health-related quality of life

    EQ-5D-5L

    Time frame: Inclusion

  125. Health-related quality of life

    EQ-5D-5L

    Time frame: 6 Months

  126. Health-related quality of life

    EQ-5D-5L

    Time frame: 1 Year

  127. Health-related quality of life

    EQ-5D-5L

    Time frame: 2 years

  128. Health-related quality of life

    EQ-5D-5L

    Time frame: 3 years

  129. Health-related quality of life

    EQ-5D-5L

    Time frame: 4 years

  130. Health-related quality of life

    EQ-5D-5L

    Time frame: 5 years

  131. Health-related quality of life

    EQ-5D-5L

    Time frame: Any relapse (maximum 5 years)

  132. Impact of MS on daily life

    Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: Inclusion

  133. Impact of MS on daily life

    Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: 6 Months

  134. Impact of MS on daily life

    Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: 1 Year

  135. Impact of MS on daily life

    Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: 2 years

  136. Impact of MS on daily life

    Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: 3 years

  137. Impact of MS on daily life

    Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: 4 years

  138. Impact of MS on daily life

    Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: 5 years

  139. Impact of MS on daily life

    Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: Any relapse (maximum 5 years)

  140. Fatigue

    Modified Fatigue Impact Scale

    Time frame: Inclusion

  141. Fatigue

    Modified Fatigue Impact Scale

    Time frame: 6 Months

  142. Fatigue

    Modified Fatigue Impact Scale

    Time frame: 1 Year

  143. Fatigue

    Modified Fatigue Impact Scale

    Time frame: 2 years

  144. Fatigue

    Modified Fatigue Impact Scale

    Time frame: 3 years

  145. Fatigue

    Modified Fatigue Impact Scale

    Time frame: 4 years

  146. Fatigue

    Modified Fatigue Impact Scale

    Time frame: 5 years

  147. Fatigue

    Modified Fatigue Impact Scale

    Time frame: Any relapse (maximum 5 years)

  148. Visual acuity

    0= low, 10= good

    Time frame: Inclusion

  149. Visual acuity

    0= low, 10= good

    Time frame: 6 Months

  150. Visual acuity

    0= low, 10= good

    Time frame: 1 Year

  151. Visual acuity

    0= low, 10= good

    Time frame: 2 years

  152. Visual acuity

    0= low, 10= good

    Time frame: 3 years

  153. Visual acuity

    0= low, 10= good

    Time frame: 4 years

  154. Visual acuity

    0= low, 10= good

    Time frame: 5 years

  155. Visual acuity

    0= low, 10 good

    Time frame: Any relapse (maximum 5 years)

  156. Low contrast visual acuity

    0= low, 10 good

    Time frame: Inclusion

  157. Low contrast visual acuity

    0= low, 10 good

    Time frame: 6 Months

  158. Low contrast visual acuity

    0= low, 10 good

    Time frame: 1 Year

  159. Low contrast visual acuity

    0= low, 10 good

    Time frame: 2 years

  160. Low contrast visual acuity

    0= low, 10 good

    Time frame: 3 years,

  161. Low contrast visual acuity

    0= low, 10 good

    Time frame: 4 years

  162. Low contrast visual acuity

    0= low, 10 good

    Time frame: 5 years

  163. Low contrast visual acuity

    0= low, 10 good

    Time frame: Any relapse (maximum 5 years)

  164. Relapse description

    monofocal, plurifocal

    Time frame: At relapse (maximum 5 years)

  165. Number of new lesions

    Measured by MRI

    Time frame: At relapse (maximum 5 years)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Mar 2027, 93 months after the start.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 93 months is above that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Jun 2026 → Mar 2027 and completion Jun 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2021
First posted
Apr 27, 2021
StartActual
Jun 25, 2019
Primary completionEst.
Mar 2027was Jun 2026
CompletionEst.
Mar 2027was Jun 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Mar 2027
Oct 22, 2026
Study completion
Jun 2026→Mar 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Jun 2026→Mar 2027
    Study completion Jun 2026→Mar 2027
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04860947
Collaborators
Institut de Recherches en Biothérapie
Responsible party
Sponsor
First posted
Apr 27, 2021
Start date
Jun 25, 2019
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Eric Thouvenot
principal investigator · CHU Nimes

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion